BLM
CLDX icon

Bennett Lawrence Management’s Celldex Therapeutics CLDX Stock Holding History

Bennett Lawrence Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-58,021
Closed -$15.4M – 93
2014
Q1 		$15.4M Buy
58,021
+21,305
+58% +$8.16M 2.28% 14
2013
Q4 		$13.3M Buy
36,716
+35,804
+3,926% +$13.8M 2.05% 15
2013
Q3 		$485K Sell
912
-2,309
-72% -$792K 0.08% 72
2013
Q2 		$754K Buy
+3,221
New +$634K 0.14% 78

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bennett Lawrence Management's CLDX Position: Q2 2014 in Review

Bennett Lawrence Management sold out of Celldex Therapeutics (CLDX) in Q2 2014, closing a stake of 58,021 shares — an estimated $15.4M sold.

Bennett Lawrence Management first reported a position in CLDX in Q2 2013 and held it in 4 quarters. The position peaked at $15.4M in Q1 2014. 135 funds tracked by Wall St. Rank hold CLDX as of Q2 2014.

  • Bennett Lawrence Management reported no remaining Celldex Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Bennett Lawrence Management sold 58,021 Celldex Therapeutics shares in Q2 2014, an estimated $15.4M.
  • Bennett Lawrence Management first reported a position in Celldex Therapeutics in Q2 2013 and held it in 4 quarters.
  • Bennett Lawrence Management's Celldex Therapeutics position peaked at $15.4M in Q1 2014.
  • 135 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2014.

Based on Bennett Lawrence Management's 13F filing for Q2 2014, filed 6 Aug 2014.